Neuron Replacement Therapy for apoE4 Carriers

About GABAeron

GABAeron is pioneering a novel therapeutic paradigm for neurodegenerative diseases by integrating cell replacement, precision genetics, and small-molecule modulation. The company's core focus is on apoE4, the strongest genetic risk factor for Alzheimer's disease, aiming to treat carriers by transplanting lab-grown inhibitory neurons to restore lost hippocampal circuitry and function. Led by renowned apoE expert Dr. Robert Mahley, the company is in the preclinical stage, working towards its first IND candidate. This strategy positions GABAeron at the intersection of regenerative and precision neurology, targeting a high-need patient population with a potentially disease-modifying approach.

Therapeutic Areas